EUVIMEDEUVIMED entdecken
Open Access

Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia

Zhenhua Li, Ti-Cheng Chang, Jacob J Junco iD, Meenakshi Devidas iD, Yizhen Li iD, Wenjian Yang iD, Xin Huang, Dale J Hedges, Zhongshan Cheng, Mary Shago, Andrew J Carroll, Nyla A Heerema und 16 weitere

Blood · 31.03.2023

DOI: 10.1182/blood.2023019765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 31.03.2023. Verfasst von Zhenhua Li und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Down Syndrome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trisomy 21, the genetic cause of Down syndrome (DS), is the most common congenital chromosomal anomaly. It is associated with a 20-fold increased risk of acute lymphoblastic leukemia (ALL) during childhood and results in distinctive leukemia biology. To comprehensively define the genomic landscape of DS-ALL, we performed whole genome sequencing and whole-transcriptome sequencing (RNA-Seq) on 295 cases. Our integrated genomic analyses identified 15 molecular subtypes of DS-ALL, with marked enrichment of CRLF2-r, IGH::IGF2BP1, and C/EBP altered (C/EBPalt) subtypes compared to 2257 non-DS-ALL cases. We observed abnormal activation of the CEBPD, CEBPA, and CEBPE genes in 10.5% of DS-ALL cases, via a variety of genomic mechanisms, including chromosomal rearrangements and noncoding mutations leading to enhancer hijacking. 42.3% of C/EBP-activated DS-ALL also have concomitant FLT3 point mutation or indel, relative to 4.1% in other subtypes (P=7.2×10-6). CEBPD overexpression enhanced the differentiation of mouse hematopoietic progenitor cells into pro-B cells in vitro, particularly in a DS genetic background. Notably, RAG-mediated somatic genomic abnormalities were common in DS-ALL, accounting for a median of 27.5% of structural alterations, compared to 7.7% in non-DS-ALL (P=2.1×10-12). Unsupervised hierarchical clustering analyses of CRLF2-rearranged DS-ALL identified substantial heterogeneity within this group, with the BCR::ABL1-like subset linked to an inferior event-free survival (hazard ratio=5.27, P=9.3×10-8), even after adjusting for known clinical risk factors (hazard ratio=4.32; P=0.0020). These results provide important insights into the biology of DS-ALL and point to opportunities for targeted therapy and treatment individualization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromePrecursor Cell Lymphoblastic Leukemia-LymphomaAnimalsMiceMutationRisk FactorsGenomicsChromosome Aberrations

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
  • Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Jacob J Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Brent L Wood, Lauren Sanclemente, Charles G Mullighan, Jiyang Yu, Philip J Lupo, Karen R Rabin

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NEI NIH HHS
  • NCRR NIH HHS
  • NIGMS NIH HHS
  • NICHD NIH HHS
  • NIEHS NIH HHS

Zitieren

APA

Li, Z., Chang, T. C., Junco, J. J., Devidas, M., Li, Y., Yang, W., Huang, X., Hedges, D. J., Cheng, Z., Shago, M., Carroll, A. J., Heerema, N. A., Gastier-Foster, J., Wood, B. L., Borowitz, M. J., Sanclemente, L., Raetz, E. A., Hunger, S. P., Feingold, E., …, & Yang, J. J. (2023). Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood.2023019765

Vancouver

Li Z, Chang TC, Junco JJ, Devidas M, Li Y, Yang W, et al. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023. doi:10.1182/blood.2023019765

BibTeX
@article{Li2023,
  author = {Li, Zhenhua and Chang, Ti-Cheng and Junco, Jacob J and Devidas, Meenakshi and Li, Yizhen and Yang, Wenjian and Huang, Xin and Hedges, Dale J and Cheng, Zhongshan and Shago, Mary and Carroll, Andrew J and Heerema, Nyla A and Gastier-Foster, Julie and Wood, Brent L and Borowitz, Michael J and Sanclemente, Lauren and Raetz, Elizabeth A and Hunger, Stephen P and Feingold, Eleanor and Rosser, Tracie C and Sherman, Stephanie L and Loh, Mignon L and Mullighan, Charles G and Yu, Jiyang and Wu, Gang and Lupo, Philip J and Rabin, Karen R and Yang, Jun J},
  title = {Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2023019765}
}
Kostenlos starten →